

ADDENDUM TO FINAL TECHNICAL REPORT

AWARD NUMBER: W81XWH-12-I-0184 (Grant number BC111520 Idea Award)

TITLE: Simultaneous Vascular Targeting and Tumor Targeting of Cerebral Breast Cancer Metastases Using a T-Cell Receptor Mimic Antibody

PRINCIPAL INVESTIGATOR: Ulrich Bickel

CONTRACTING ORGANIZATION: Texas Tech University Health Sciences Center

REPORT DATE: 07-24-2018

TYPE OF REPORT: Addendum to Final Technical Report, Revised Section 6. "Products, Inventions, Patent Application and/or Licenses"

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE 07-24-2018			2. REPORT TYPE Addendum to Final Technical Report		3. DATES COVERED 05-01-2012 to 04-30-2016	
4. TITLE AND SUBTITLE Simultaneous Vascular Targeting and Tumor Targeting of Cerebral Breast Cancer Metastases Using a T-Cell Receptor Mimic Antibody					5a. CONTRACT NUMBER W81XWH-12-1-0184	
					5b. GRANT NUMBER BC111520	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Ulrich Bickel E-Mail: Ulrich.Bickel@ttuhsc.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Texas Tech University Health Sciences Center 3601 4th Street Lubbock, TX 79430					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT						
15. SUBJECT TERMS						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)	

ADDENDUM TO FINAL TECHNICAL REPORT

Revised Section 6. PRODUCT

Inventions, patent applications, and/or licenses*

*Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number.**

(The above instruction is taken from the language in Section 6 of the reporting requirements. Is there additional information that you normally receive or expect to receive from the PI in this section, i.e., a general description of the invention/patent, etc.?)

A provisional patent application had been filed with the US PTO originally in March of 2012, before the DoD grant was awarded. During the grant period there were several rounds of comments by PTO reviewers and responses by the inventors, before the patent was finally awarded on January 31, 2017 (US 9,555,108 B2). The experiments performed for the DoD grant yielded data, which were in part used to address the patent reviewer's concerns.

From the patent abstract: The invention includes a method of delivering a therapeutic agent into and across an endothelial cell (EC) in a subject in need thereof, comprising: attaching to a T Cell receptor mimic (TCR mimic) an active agent to form a therapeutic agent; and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent effectively crosses the EC microvascular barrier. Furthermore, the present invention relates to methods of treating diseases (particularly neuronal diseases) or conditions comprising identifying a subject in need of such a treatment and administering to said subject a composition comprising a TCR mimic conjugated to an active agent.

*The paragraph in your award entitled "Patents and Inventions Reporting Requirements" requires you to submit a final DD Form 882, "Report of Inventions and Subcontracts " and file invention disclosures and patent applications using the Interagency Edison (iEdison) system through the National Institutes of Health. Do not include the form or copy of the iEdison report in this addendum. Submit as instructed in the paragraph.